NASDAQ$BLFS
BioLife Solutions Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
BioLife Solutions reported a revenue increase of 19% year-over-year, driven by growth in cell processing and biopreservation media.
BioLife Solutions reported Q4 2022 revenue of $44.3 million, a 19% increase year-over-year. The company reported an adjusted EBITDA of $1.7 million for the quarter and ended the year with $64.1 million in cash and short-term investments. The company reaffirms 2023 revenue guidance of $188 million to $202 million.
- Q4 2022 revenue increased by 19% year-over-year to $44.3 million.
- Biopreservation media revenue grew by 35%.
- Adjusted EBITDA for Q4 2022 was $1.7 million.
- The company gained 217 new customers in Q4 2022.
Headline financials
Revenue & EPS history
BioLife · Revenue · Quarterly
$44.3M
Revenue by segment
BioLife · $20.2M total across 1 segment · Q4 2022
- Cell Processing platform$20.2M+36.5%100.0%
Forward guidance
BioLife Solutions reaffirms 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Tailwinds
- Approvals of new cell and gene therapies
- Additional approvals of commercial CGT in new geographies
- Additional approvals of CGT in new indications
- Migration of commercial therapies to first or second-line treatment
- An eventual transition to allogeneic therapies
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+4.3%
Avg return
30 days after
44%
22 / 50 earnings
Positive
+21.4%
Q3 2022
Best reaction
-34.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.3% | -2.4% | +22.4% | |
| Q4 2025 | +8.0% | -8.1% | -17.3% | |
| Q3 2025 | -4.2% | -4.1% | -5.8% | |
| Q2 2025 | +10.0% | +24.4% | +28.2% | |
| Q1 2025 | +4.0% | -1.4% | +6.0% | |
| Q4 2024 | +2.1% | +7.6% | -0.9% | |
| Q3 2024 | -9.4% | -21.0% | +0.5% | |
| Q2 2024 | +14.5% | +20.3% | +7.9% | |
| Q1 2024 | +8.9% | +25.0% | +13.2% | |
| Q4 2023 | +5.1% | -0.5% | +8.5% | |
| Q3 2023 | -5.7% | +3.1% | +14.2% | |
| Q2 2023 | -29.7% | -34.9% | -30.3% | |
| Q1 2023 | -2.9% | +3.5% | +20.6% | |
| Q4 2022 | +0.2% | +2.7% | -7.4% | |
| Q3 2022 | +21.4% | +14.1% | -4.6% | |
| Q2 2022 | +13.7% | +15.7% | +25.6% | |
| Q1 2022 | -3.8% | +1.6% | +18.3% | |
| Q4 2021 | -0.3% | +0.9% | -3.7% | |
| Q3 2021 | -6.0% | +5.2% | -30.3% | |
| Q2 2021 | -1.8% | -3.9% | +12.0% | |
| Q1 2021 | -2.1% | +4.8% | +25.1% | |
| Q4 2020 | +8.3% | -7.8% | -14.7% | |
| Q3 2020 | +5.8% | +0.8% | +21.6% | |
| Q2 2020 | +0.3% | -5.4% | +5.6% | |
| Q1 2020 | +3.0% | +10.5% | +1.5% | |
| Q4 2019 | -34.5% | -36.7% | -27.8% | |
| Q3 2019 | -12.8% | -8.8% | -7.4% | |
| Q2 2019 | -6.2% | +1.1% | +7.7% | |
| Q1 2019 | -2.4% | +4.5% | +8.8% | |
| Q4 2018 | +10.7% | +19.4% | +5.5% | |
| Q3 2018 | +15.0% | -8.0% | -7.8% | |
| Q2 2018 | -4.8% | -1.0% | +2.3% | |
| Q1 2018 | -3.7% | +7.6% | +23.5% | |
| Q4 2017 | -4.4% | -10.2% | +22.4% | |
| Q3 2017 | +18.0% | +21.6% | +8.2% | |
| Q2 2017 | +3.8% | +8.2% | +30.6% | |
| Q1 2017 | +3.7% | -1.4% | +7.8% | |
| Q4 2016 | -5.0% | -9.5% | -7.7% | |
| Q3 2016 | +0.7% | +2.7% | +5.4% | |
| Q2 2016 | -2.4% | -7.7% | -15.9% | |
| Q3 2012 | +10.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -14.3% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -11.1% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro